Analysts Anticipate Evelo Biosciences Inc (NASDAQ:EVLO) to Post -$0.65 EPS

Brokerages expect Evelo Biosciences Inc (NASDAQ:EVLO) to announce ($0.65) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Evelo Biosciences’ earnings. The highest EPS estimate is ($0.63) and the lowest is ($0.67). Evelo Biosciences posted earnings per share of ($0.49) in the same quarter last year, which would suggest a negative year-over-year growth rate of 32.7%. The company is expected to announce its next earnings results on Thursday, February 13th.

According to Zacks, analysts expect that Evelo Biosciences will report full-year earnings of ($2.54) per share for the current year, with EPS estimates ranging from ($2.67) to ($2.40). For the next year, analysts expect that the company will post earnings of ($2.29) per share, with EPS estimates ranging from ($2.40) to ($2.18). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Evelo Biosciences.

Evelo Biosciences (NASDAQ:EVLO) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.67) earnings per share for the quarter, meeting the consensus estimate of ($0.67).

Separately, Zacks Investment Research raised shares of Evelo Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, January 8th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $12.17.

Hedge funds have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its holdings in shares of Evelo Biosciences by 7.5% in the second quarter. Charles Schwab Investment Management Inc. now owns 44,103 shares of the company’s stock worth $397,000 after buying an additional 3,088 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Evelo Biosciences by 15.0% in the second quarter. Morgan Stanley now owns 64,206 shares of the company’s stock worth $576,000 after buying an additional 8,366 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Evelo Biosciences by 1.3% in the second quarter. BlackRock Inc. now owns 654,753 shares of the company’s stock worth $5,879,000 after buying an additional 8,520 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Evelo Biosciences by 1.6% in the second quarter. Northern Trust Corp now owns 139,200 shares of the company’s stock worth $1,250,000 after buying an additional 2,202 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Evelo Biosciences by 36.5% in the second quarter. Bank of New York Mellon Corp now owns 43,599 shares of the company’s stock worth $392,000 after buying an additional 11,667 shares in the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:EVLO traded up $0.75 during trading hours on Wednesday, hitting $5.37. 95,400 shares of the stock traded hands, compared to its average volume of 76,071. The company has a quick ratio of 10.46, a current ratio of 10.46 and a debt-to-equity ratio of 0.24. Evelo Biosciences has a 1 year low of $3.58 and a 1 year high of $10.09. The company has a market cap of $139.25 million, a price-to-earnings ratio of -2.19 and a beta of -0.35. The stock has a 50 day moving average price of $4.22 and a 200 day moving average price of $5.95.

Evelo Biosciences Company Profile

Evelo Biosciences, Inc, a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases.

Featured Article: What are the benefits of investing in REITs?

Get a free copy of the Zacks research report on Evelo Biosciences (EVLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.